Latest Capital Raises News

NOVONIX Limited reports progress scaling its Chattanooga synthetic graphite plant, secures major funding, and benefits from U.S. tariffs on Chinese imports, while narrowing its half-year loss.

Omnia Metals Group Limited has issued a prospectus to list up to 10,000 options, aiming to remove trading restrictions and facilitate secondary market activity. This move follows recent capital raisings and shareholder approvals, positioning the company for enhanced liquidity.

DigitalX Limited has boosted its treasury valuation to A$104 million, driven by a strategic Bitcoin-first approach that now totals nearly 500 BTC. The company aims to more than quadruple its Bitcoin holdings by 2027, underscoring its confidence in digital assets as a core treasury component.

CLINUVEL Pharmaceuticals is preparing to elevate its American Depository Receipt program to a Nasdaq Level II listing by the end of 2025, aiming to enhance visibility and trading access in the U.S. without altering its primary ASX listing.

Beacon Minerals has exercised its option to acquire the historic Wealth of Nations gold tenements, confirming high-grade mineralisation through an 11-hole drill program and setting the stage for a maiden resource estimate in 2026.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

Larvotto Resources has raised $10 million through a Share Purchase Plan, bolstering its financial position as it advances the Hillgrove Project toward production slated for Q2 2026.

DUG Technology reported a record US$52 million order book and strong second-half momentum in FY25, driven by innovative seismic imaging technology and global office expansions despite a slight revenue dip.

DUG Technology reports a landmark US$52 million services order book for FY25 despite a net loss, driven by new imaging tech and mobile data centre launches.

Arovella Therapeutics reported a 14% reduction in net loss to $7.5 million for FY25, bolstered by a $15 million capital raise to fund its lead iNKT cell therapy program progressing toward a pivotal phase 1 clinical trial.

AMA Group reported a robust FY25 with revenue surpassing $1 billion and a 38% jump in normalized EBITDA, underpinned by operational improvements and a strengthened balance sheet.

AMA Group Limited reported a robust FY25 with revenue climbing 8.6% to over $1 billion and a 38.4% jump in normalised EBITDA, while significantly reducing net debt following a major equity raise and debt refinancing.